| ALCON |
ALCON |
92%
|
YD Bio’s top three corporate customers — Novartis, Zuelling and Alcon — accounted for approximately 53.7% of the company’s total revenue for the year ended December 31, 2025. |
| NVS |
Novartis AG |
92%
|
YD Bio’s top three corporate customers — Novartis, Zuelling and Alcon — accounted for approximately 53.7% of the company’s total revenue for the year ended December 31, 2025. |
| NVS |
Novartis AG |
92%
|
Reciprocal relationship from NVS graph: Reciprocal relationship from YDES graph: Reciprocal relationship from NVS graph: Reciprocal relationship from YDES graph: YD Bio’s top three corporate customer… |
| ZUELLING |
ZUELLING |
92%
|
YD Bio’s top three corporate customers — Novartis, Zuelling and Alcon — accounted for approximately 53.7% of the company’s total revenue for the year ended December 31, 2025. |
| BNR |
Burning Rock Biotech Limited |
72%
|
ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s top two corporate customers, Alcon and Novartis, contributed approximately 54.7% of … |
| BNR |
Burning Rock Biotech Limited |
72%
|
Reciprocal relationship from BNR graph: Reciprocal relationship from YDES graph: Reciprocal relationship from BNR graph: Reciprocal relationship from YDES graph: Reciprocal relationship from BNR grap… |
| CAPR |
Capricor Therapeutics, Inc. |
72%
|
Reciprocal relationship from CAPR graph: Reciprocal relationship from YDES graph: Reciprocal relationship from CAPR graph: Reciprocal relationship from YDES graph: Reciprocal relationship from CAPR g… |
| CAPR |
Capricor Therapeutics, Inc. |
72%
|
ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s top two corporate customers, Alcon and Novartis, contributed approximately 54.7% of … |
| EXAS |
Exact Sciences Corp |
72%
|
Reciprocal relationship from EXAS graph: Reciprocal relationship from YDES graph: ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s to… |
| EXAS |
Exact Sciences Corp |
72%
|
ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s top two corporate customers, Alcon and Novartis, contributed approximately 54.7% of … |
| GH |
Guardant Health, Inc. |
72%
|
Reciprocal relationship from GH graph: Reciprocal relationship from YDES graph: Reciprocal relationship from GH graph: Reciprocal relationship from YDES graph: Reciprocal relationship from GH graph: … |
| GH |
Guardant Health, Inc. |
72%
|
ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s top two corporate customers, Alcon and Novartis, contributed approximately 54.7% of … |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from YDES graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from YDES graph: Reciprocal relationship from JNJ grap… |
| JNJ |
Johnson & Johnson |
72%
|
ontributed approximately 53.7% of the Company’s total revenue. For the year ended December 31, 2024, the Company’s top two corporate customers, Alcon and Novartis, contributed approximately 54.7% of … |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
s. Decreasing demand from our customers or increased prices quoted by our suppliers may materially and adversely affect our future results of operations. Risks Related to Intellectual Property Rights… |
| YC-BIOTECH-CO-LTD |
YC-BIOTECH-CO-LTD |
62%
|
a total consideration of approximately NT$839,832,000. The acquisition is expected to involve a combination of newly issued Ordinary Shares and cash. This acquisition is intended to enhance our R&D c… |
